|Bid||68.63 x 1400|
|Ask||68.75 x 900|
|Day's Range||61.54 - 74.00|
|52 Week Range||22.22 - 74.00|
|Beta (3Y Monthly)||3.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.96|
Crispr Therapeutics AG (NASDAQ: CRSP ) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's ...
The gene-editing technique known as Crispr/Cas9 produced promising early-stage results, sending shares of Crispr Therapeutics and Vertex Pharmaceuticals higher.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
Shares of Crispr Therapeutics jumped Tuesday after the biotech company's gene-editing approach to sickle cell disease and beta thalassemia, both blood diseases, showed early promise.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
-Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous.
Advanced Micro Devices Inc. (AMD) jumped 81 cents to $37.52 on 67 million shares traded Wednesday. Amarin Corp. PLC (AMRN) followed through on Wednesday, up 55 cents to $21.49 after popping 23% on Tuesday. An FDA advisory committee is scheduled to meet today to help decide the fate of the company’s fish-derived cardiovascular drug.
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
Current ratio is a popular way for investors to assess the health of a stock’s balance sheet. Current ratio is a measure of a company’s ability to pay its current liabilities and obligations due within ...
State Street, General Electric and Raytheon are among the local companies with executives speaking at the Future Investment Initiative.
BTIG sees Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s decision to exercise its options to in-license three additional targets as one that further integrated the operations of the two companies, fueling speculation that Vertex could end up buying Crispr.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 352.63% and 3252.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Began treating patients in Phase 1/2 clinical trial of.
During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR.
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.